• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by SWK Holdings Corporation

    3/31/26 4:15:36 PM ET
    $SWKH
    Diversified Financial Services
    Finance
    Get the next $SWKH alert in real time by email
    425 1 e26163_swkh-8k.htm SWKH 8-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of Earliest Event Reported): March 31, 2026

     

    SWK HOLDINGS CORPORATION

    (Exact Name of the Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction of Incorporation)

     

    001-39184 77-0435679
    (Commission File Number) (IRS Employer Identification No.)
       
    5956 Sherry Lane, Suite 650, Dallas, TX 75225
    (Address of Principal Executive Offices) (Zip Code)

     

    (972) 687-7250

    (Registrant’s Telephone Number, Including Area Code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

     

    Title of each class

     

    Trading Symbol(s)

    Name of each exchange on

    which registered

    Common Stock, par value

    $0.001 per share

    SWKH The Nasdaq Stock Market LLC
    9.00% Senior Notes due 2027 SWKHL The Nasdaq Stock Market LLC

      

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On March 31, 2026, SWK Holdings Corporation (the “Company” or “SWK”) held a special meeting of stockholders (the “Special Meeting”) to consider and vote on the proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 3, 2026 (the “Proxy Statement”).

     

    As of the close of business on March 2, 2026, the record date for the Special Meeting (the “Record Date”), there were 12,095,906 issued and outstanding shares of SWK common stock, par value $0.001 per share (“SWK Common Stock”), entitled to vote at the Special Meeting. At the Special Meeting, the holders of a total of 11,256,673 shares of SWK Common Stock, representing 93.06% of the shares of SWK Common Stock entitled to vote at the Special Meeting, were represented in person or by proxy, constituting a quorum. The final results for the votes regarding each proposal are set forth below.

     

    Proposal 1 - The Merger Agreement Proposal

     

    Proposal 1 (the “Merger Agreement Proposal”) was to consider and vote to adopt Agreement and Plan of Merger, dated as of October 9, 2025 (as may be amended from time to time, the “Merger Agreement”), by and among Runway Growth Finance Corp., a Maryland corporation (“Parent” or “RWAY”); SWK; RWAY Portfolio Holding Corp., a Delaware corporation and a direct wholly-owned subsidiary of RWAY (“Intermediary Sub”); RWAY Portfolio Corp., a Delaware corporation and a direct wholly-owned subsidiary of Intermediary Sub (“Acquisition Sub”); and Runway Growth Capital LLC, a Delaware limited liability company and the external investment adviser to RWAY and approve the merger of SWK with and into Acquisition Sub, with Acquisition Sub continuing as the surviving company and as a wholly-owned subsidiary of Intermediary Sub (the “First Merger” and together with the other transactions contemplated under the Merger Agreement, the “Mergers”). The results with respect to the Merger Agreement Proposal are set forth below and the proposal was approved:

                 
    Votes For   Votes
    Against
      Abstentions   Broker Non-Votes
    11,240,819   8,763   7,091   -

     

    Proposal 2 - The Compensation Proposal

     

    Proposal 2 (the “Compensation Proposal”) was to consider and vote to approve, on a non-binding advisory basis, the compensation that may be paid or become payable to SWK’s named executive officers, in connection with the Mergers.

     

    The results with respect to the Compensation Proposal are set forth below and the proposal was approved:

                 
    Votes For   Votes
    Against
      Abstentions   Broker Non-Votes
    11,214,361   38,992   3,320   -

      

    Proposal 3 - The Director Compensation Proposal

     

    Proposal 3 (the “Director Compensation Proposal”) was to consider and vote to approve the compensation that may be paid or become payable to each member of the SWK Board of Directors in connection with the Mergers.

     

    The results with respect to the Director Compensation Proposal are set forth below and the proposal was approved:

                 
    Votes For   Votes
    Against
      Abstentions   Broker Non-Votes
    11,140,460   92,615   23,598   -

     

    Proposal 4 - The Adjournment Proposal

     

    Proposal 4 (the “Adjournment Proposal”) was to consider and vote to approve one or more adjournments of the Special Meeting if necessary to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Merger Proposal (as described in the Proxy Statement). The Adjournment Proposal was not voted on at the Special Meeting because there were sufficient votes to then approve the Merger Agreement Proposal.

     

     

     

    Forward-Looking Statements

     

    Some of the statements in this Current Report on Form 8-K constitute forward-looking statements because they relate to future events, future performance or financial condition. The forward-looking statements may include statements as to future operating results of Parent and the Company, and distribution projections; business prospects of Parent and the Company, and the prospects of their portfolio companies; and the impact of the investments that Parent and the Company expect to make. In addition, words such as “anticipate,” “believe,” “expect,” “seek,” “plan,” “should,” “estimate,” “project” and “intend” indicate forward-looking statements, although not all forward-looking statements include these words. The forward-looking statements contained in this document involve risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected, including the uncertainties associated with (i) the ability of the parties to consummate the mergers on the expected timeline, or at all; (ii) the expected synergies and savings associated with the mergers; (iii) the ability to realize the anticipated benefits of the mergers, including the expected elimination of certain expenses and costs due to the mergers; (iv) the possibility that any or all of the various conditions to the consummation of the mergers may not be satisfied or waived; (v) risks related to diverting management’s attention from ongoing business operations; (vi) the combined company’s plans, expectations, objectives and intentions, as a result of the mergers; (vii) any potential termination of the merger agreement; (viii) the future operating results and net investment income projections of Parent, the Company or, following the closing of the mergers, the combined company; (ix) the ability of the Adviser and its affiliates to attract and retain highly talented professionals; (x) the business prospects of Parent, the Company or, following the closing of the mergers, the combined company, and the prospects of their portfolio companies; (xi) the impact of the investments that Parent, the Company or, following the closing of the mergers, the combined company expect to make; (xii) the ability of the portfolio companies of Parent, the Company or, following the closing of the mergers, the combined company to achieve their objectives; (xiii) the expected financings and investments and additional leverage that Parent, the Company or, following the closing of the mergers, the combined company may seek to incur in the future; (xiv) the adequacy of the cash resources and working capital of Parent, the Company or, following the closing of the mergers, the combined company; (xv) the timing of cash flows, if any, from the operations of the portfolio companies of Parent, the Company or, following the closing of the mergers, the combined company; (xvi) the risk that stockholder litigation in connection with the mergers may result in significant costs of defense and liability; and (xvii) future changes in laws or regulations (including the interpretation of these laws and regulations by regulatory authorities). You should not place undue reliance on such forward-looking statements, which speak only as of the date of this communication. Parent and the Company have based the forward-looking statements included in this document on information available to them on the date hereof, and they assume no obligation to update any such forward-looking statements. Although Parent and the Company undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that they may make directly to you or through reports that Parent and the Company in the future may file with the U.S. Securities and Exchange Commission (the “SEC”), including the Company’s annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. You should read this communication and the documents referenced in this communication completely and with the understanding that actual future events and results may be materially different from expectations. Parent and the Company qualify all forward-looking statements by these cautionary statements.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

      SWK HOLDINGS CORPORATION
         
      By: /s/ Joe D. Staggs
        Joe D. Staggs
        President and Chief Executive Officer

     

    Date: March 31, 2026

     

     
    Get the next $SWKH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SWKH

    DatePrice TargetRatingAnalyst
    12/28/2022$26.00Buy
    Lake Street
    4/18/2022$26.00Buy
    Lake Street
    More analyst ratings

    $SWKH
    SEC Filings

    View All

    SEC Form 425 filed by SWK Holdings Corporation

    425 - SWK Holdings Corp (0001089907) (Subject)

    3/31/26 4:15:36 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SWK Holdings Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - SWK Holdings Corp (0001089907) (Filer)

    3/31/26 4:15:17 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form 10-K filed by SWK Holdings Corporation

    10-K - SWK Holdings Corp (0001089907) (Filer)

    3/20/26 4:30:24 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on SWK Holdings with a new price target

    Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

    12/28/22 9:18:49 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Lake Street initiated coverage on SWK Holdings with a new price target

    Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

    4/18/22 8:44:23 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Runway Growth Finance Corp. to Acquire SWK Holdings Corporation

    Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi

    10/9/25 5:45:24 PM ET
    $RWAY
    $SWKH
    Finance: Consumer Services
    Finance
    Diversified Financial Services

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    ImpediMed Secures $15m Growth Capital Funding

    New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv

    2/7/25 11:00:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hatcher Robert K. was granted 3,858 shares, increasing direct ownership by 30% to 16,662 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:16:45 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    Director Albright Jerry was granted 3,858 shares, increasing direct ownership by 55% to 10,832 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:16:24 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    Director Dotter Laurie L. was granted 3,858 shares, increasing direct ownership by 30% to 16,791 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:15:58 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Leadership Updates

    Live Leadership Updates

    View All

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

    January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

    1/22/25 8:30:00 AM ET
    $BDRX
    $JNJ
    $SWKH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Financial Services
    Finance

    SWK Holdings Appoints Chief Financial Officer

    Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC

    7/8/24 5:00:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Financials

    Live finance-specific insights

    View All

    Runway Growth Finance Corp. to Acquire SWK Holdings Corporation

    Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi

    10/9/25 5:45:24 PM ET
    $RWAY
    $SWKH
    Finance: Consumer Services
    Finance
    Diversified Financial Services

    SWK Holdings Corporation Announces Financial Results for Third Quarter 2024

    Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2

    11/14/24 4:15:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SWK Holdings Provides Portfolio Update

    Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

    10/17/24 4:15:00 PM ET
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SWKH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SWK Holdings Corporation

    SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

    11/14/24 11:49:47 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Amendment: SEC Form SC 13D/A filed by SWK Holdings Corporation

    SC 13D/A - SWK Holdings Corp (0001089907) (Subject)

    10/25/24 4:05:56 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

    SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

    2/14/24 2:14:12 PM ET
    $SWKH
    Diversified Financial Services
    Finance